Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027KT-621 BREADTH Phase 2b trial in asthma on track to ...
PharmiWeb

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...
Medscape

Transplant Recipients at Higher Risk for Several Comorbidities, Study Suggests

A retrospective study found a higher prevalence of several autoimmune and inflammatory conditions, in addition to skin ...
The Clinton Herald

TO YOUR GOOD HEALTH: Big changes in height and weight should prompt an evaluation

Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible.